Intraocular Inflammation following Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in Japanese Patients: Meta analysis using individual patient data

Intraocular Inflammation following Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in Japanese Patients: Meta analysis using individual patient data - Individual data analysis of Intraocular Inflammation following Intravitreal Brolucizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049461

Enrollment

1080

Registered

2022-11-08

Start date

2022-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nAMD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects were Japanese nAMD patients who treated with IVBr for nAMD at least one time.

Exclusion criteria

Exclusion criteria: Patients were excluded if he/she had a prophylactic treatment(s) for IOI, including topical administration of steroids

Design outcomes

Primary

Measure	Time frame
Risk factors of IOI following IVBr (gender, age, the number of IVBr before IOI onset, history of smoking, HT, DM, RV/RO and the treatment of nAMD)	—

Countries

Japan

Contacts

Public ContactSatoru Inoda

Jichi Medical University Ophthalmology

r1208is@jichi.ac.jp0285-58-7382

Outcome results